Announcements Trials
Browse Landscape

Phase

Phase 2 30Phase 1 19Phase 3 6Phase 1/2 3Phase EARLY_PHASE1 2Phase 2/3 2Phase NA 1Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Infiltrating Bladder Urothelial Carcinoma 1

Interventions

Exercise 419Blood Specimen Collection 319Standard of Care 299Surveys and Questionnaires 241Radiosurgery 239Magnetic Resonance Spectroscopy 232Educational Status 223Methods 221Radiotherapy 216Early Intervention, Educational 200Interviews as Topic 142Practice Guidelines as Topic 141Biopsy 125Surgical Procedures, Operative 119Drug Therapy 119Acupuncture Therapy 119Control Groups 115Therapeutics 100Palliative Care 97Resistance Training 94Counseling 88Saline Solution 87Magnetic Resonance Imaging 84Cyclophosphamide 83Specimen Handling 73Cisplatin 73Radiofrequency Ablation 71Cognitive Behavioral Therapy 71Radiotherapy, Intensity-Modulated 68Colonoscopy 65

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × OTHER × 1,2-diaminocyclohexaneplatinum II citrate × Clear all
NCT02944357 2017-11-17

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

Mayo Clinic

Phase NA Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡